Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis SCLM Cremers, G Pillai, SE Papapoulos Clinical pharmacokinetics 44, 551-570, 2005 | 330 | 2005 |
Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions MC Kjellsson, LE Via, A Goh, D Weiner, KM Low, S Kern, G Pillai, ... Antimicrobial agents and chemotherapy 56 (1), 446-457, 2012 | 206 | 2012 |
Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption JJ Wilkins, RM Savic, MO Karlsson, G Langdon, H McIlleron, G Pillai, ... Antimicrobial agents and chemotherapy 52 (6), 2138-2148, 2008 | 201 | 2008 |
Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients JJ Wilkins, G Langdon, H McIlleron, G Pillai, PJ Smith, USH Simonsson British journal of clinical pharmacology 72 (1), 51-62, 2011 | 136 | 2011 |
Non-linear mixed effects modeling–from methodology and software development to driving implementation in drug development science G Pillai, F Mentré, JL Steimer Journal of pharmacokinetics and pharmacodynamics 32, 161-183, 2005 | 133 | 2005 |
A semimechanistic and mechanistic population PK–PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis G Pillai, R Gieschke, T Goggin, P Jacqmin, RC Schimmer, JL Steimer British journal of clinical pharmacology 58 (6), 618-631, 2004 | 108 | 2004 |
Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients JJ Wilkins, G Langdon, H McIlleron, G Pillai, PJ Smith, USH Simonsson European journal of clinical pharmacology 62, 727-735, 2006 | 107 | 2006 |
Recent bioequivalence studies on fixed-dose combination anti-tuberculosis drug formulations available on the global market G Pillai, PB Fourie, N Padayatchi, PC Onyebujoh, H McIlleron, PJ Smith, ... The International Journal of Tuberculosis and Lung Disease 3 (11), S309-S316, 1999 | 99 | 1999 |
Longitudinal model‐based meta‐analysis in rheumatoid arthritis: an application toward model‐based drug development I Demin, B Hamrén, O Luttringer, G Pillai, T Jung Clinical Pharmacology & Therapeutics 92 (3), 352-359, 2012 | 61 | 2012 |
Additional renal veins: incidence and morphometry KS Satyapal, V Rambiritch, G Pillai Clinical Anatomy: The Official Journal of the American Association of …, 1995 | 58 | 1995 |
A retrospective study of human immunodeficiency virus infection and drug-resistant tuberculosis in Durban, South Africa D Anastasis, G Pillai, V Rambiritch, SS Abdool Karim The International Journal of Tuberculosis and Lung Disease 1 (3), 220-224, 1997 | 46 | 1997 |
Morphometric analysis of the renal veins KS Satyapal, V Rambiritch, G Pillai The anatomical record 241 (2), 268-272, 1995 | 39 | 1995 |
Care-seeking dynamics among patients with diabetes mellitus and hypertension in selected rural settings in Kenya M Karinja, G Pillai, R Schlienger, M Tanner, B Ogutu International journal of environmental research and public health 16 (11), 2016, 2019 | 35 | 2019 |
The Next Generation Scientist program: capacity-building for future scientific leaders in low-and middle-income countries G Pillai, K Chibale, EC Constable, AN Keller, MM Gutierrez, F Mirza, ... BMC Medical Education 18, 1-11, 2018 | 35 | 2018 |
Population pharmacodynamic model of the longitudinal FEV1 response to an inhaled long-acting anti-muscarinic in COPD patients K Wu, M Looby, G Pillai, G Pinault, AF Drollman, S Pascoe Journal of pharmacokinetics and pharmacodynamics 38, 105-119, 2011 | 33 | 2011 |
Pharmacokinetic similarity of biologics: analysis using nonlinear mixed‐effects modeling A Dubois, S Gsteiger, S Balser, E Pigeolet, JL Steimer, G Pillai, F Mentré Clinical Pharmacology & Therapeutics 91 (2), 234-242, 2012 | 32 | 2012 |
Open-source mobile digital platform for clinical trial data collection in low-resource settings J Van Dam, KO Onyango, B Midamba, N Groosman, N Hooper, J Spector, ... BMJ innovations 3 (1), 2017 | 28 | 2017 |
Pharmacometrics: opportunity for reducing disease burden in the developing world: the case of Africa G Pillai, G Davies, P Denti, JL Steimer, H McIlleron, S Zvada, E Chigutsa, ... CPT: pharmacometrics & systems pharmacology 2 (8), 1-4, 2013 | 28 | 2013 |
Establishing the bioequivalence of rifampicin in fixed dose formulations containing isoniazid with or without pyrazinamide and/or ethambutol compared to single drug reference … B Fourie, G Pillai, H McIlleron, P Smith, R Panchagnula, G Ellard, ... World Health Organization, WHO/CDS/TB/99.274 1999, 1999 | 28* | 1999 |
Targeted chemotherapy for parasite infestations in rural black preschool children M Taylor, G Pillai, JD Kvalsvig South African Medical Journal 85 (9), 1995 | 27 | 1995 |